TVRD Key Statistics, Chart & Performance
The current stock price of TVRD is 3.93 USD. In the past month the price decreased by -5.98%.
TVRD Latest News, Press Relases and Analysis
TVRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About TVRD
Company Profile
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Company Info
TVARDI THERAPEUTICS INC
3 Sugar Creek Ctr Blvd, Ste 525
Sugar Land TEXAS US
Employees: 10
Phone: 17134898654
TVARDI THERAPEUTICS INC / TVRD FAQ
What does TVRD do?
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
What is the stock price of TVARDI THERAPEUTICS INC today?
The current stock price of TVRD is 3.93 USD. The price decreased by -2.48% in the last trading session.
Does TVRD stock pay dividends?
TVRD does not pay a dividend.
How is the ChartMill rating for TVARDI THERAPEUTICS INC?
TVRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about TVARDI THERAPEUTICS INC (TVRD) stock?
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 285.6% is expected in the next year compared to the current price of 3.93.
Would investing in TVARDI THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TVRD.
Can you provide the upcoming earnings date for TVARDI THERAPEUTICS INC?
TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2026-03-09, after the market close.
TVRD Technical Analysis
TVRD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TVRD. TVRD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TVRD Financial Highlights
Over the last trailing twelve months TVRD reported a non-GAAP Earnings per Share(EPS) of -78.48. The EPS decreased by -37.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVRD Forecast & Estimates
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 285.6% is expected in the next year compared to the current price of 3.93.
For the next year, analysts expect an EPS growth of 98.33% and a revenue growth -82.49% for TVRD